EUVIMEDEUVIMED entdecken
Crossref

A Multistate Investigation of Serious Adverse Events, Including Deaths, Following Ceftriaxone Injections, September 2024–August 2025

Eine Untersuchung schwerer unerwünschter Ereignisse, einschließlich Todesfällen, nach Ceftriaxon-Injektionen in mehreren Bundesstaaten, September 2024–August 2025

Rebecca Pierce iD, Radhika Agarwal iD, Dumbani Kayira, Maribeth C Lovegrove iD, Nimalie D Stone iD, Kelly M Hatfield iD, Jennifer Lind Lyles iD, Melissa Morrison iD, Wes Stubblefield, Sherri L Davidson, Karen Landers, Scott Harris iD und 29 weitere

Clinical Infectious Diseases · 03.09.2026

DOI: 10.1093/cid/ciag521 ↗

Auf einen Blick

Bei 31 Fällen nach Ceftriaxon-Injektion traten schwere unerwünschte Ereignisse auf, darunter Todesfälle und Reanimationen. Produktprüfungen und Trendanalysen ergaben keinen Hinweis auf ein neues Sicherheitsproblem.

Fragestellung

Wurden nach Ceftriaxon-Injektionen schwere unerwünschte Ereignisse beschrieben, und gibt es Hinweise auf ein neues Sicherheitsproblem?

Methode

Bundesweite Falldefinition, Datenerhebung durch Gesundheitsbehörden und CDC; Laborprüfung von Ceftriaxon und Lidocain-Verdünner durch die FDA; Trendanalysen mit Medicare- und NEISS-CADES-Daten.

Ergebnisse

31 Fälle aus 27 Einrichtungen in 18 Bundesstaaten; 12 Personen starben, 23 hatten anaphylaxieähnliche Verläufe, 21 hatten frühere Ceftriaxon-Exposition und 24 kardiale Komorbiditäten. Trends blieben stabil.

Schlussfolgerung der Autor:innen

Schwere unerwünschte Ereignisse, einschließlich Todesfällen, können nach Ceftriaxon auftreten. Produktprüfung und Trendanalysen zeigten keinen Hinweis auf ein neues Sicherheitsproblem.

Kernaussagen

  • 31 Fälle nach Ceftriaxon-Injektion
  • 12 Personen starben; 23 Fälle mit anaphylaxieähnlicher Präsentation
  • Kein Hinweis auf Tampering, Adulteration oder neues Sicherheitsproblem

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 03.09.2026. Verfasst von Rebecca Pierce und 40 weiteren Autor:innen. Beteiligte Einrichtung: Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, …. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Centers for Disease Control and Prevention.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Reports of ceftriaxone serious adverse events (SAEs), including deaths, from multiple jurisdictions during December 2024–January 2025 prompted a nationwide investigation to evaluate product safety, characterize SAEs, and assess for changes in baseline adverse event occurrence via national databases.

Methods

In February 2025, the Centers for Disease Control and Prevention issued a national call for cases, defined as SAEs involving death or cardiopulmonary resuscitation within 6 hours of ceftriaxone injection, not otherwise explained and occurring in non–intensive care unit settings during September 2024–August 2025. Epidemiologic and clinical data were collected by health departments and reported to the Centers for Disease Control and Prevention. Laboratory testing of ceftriaxone and lidocaine diluent was performed at Food and Drug Administration. Temporal trends in adverse events (2016–2019 vs 2020–2024) were assessed via Medicare claims and National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance System analyses.

Results

Among 31 cases identified from 27 healthcare facilities (65% outpatient) across 18 states during September 2024–August 2025, all involving death or cardiopulmonary resuscitation, 12 (39%) persons died, 23 (74%) had anaphylaxis-type presentations (65% without skin/mucosal involvement), 21 (68%) had previous ceftriaxone exposure, and 24 (77%) had cardiac comorbidities. Median age was 67 years (interquartile range: 60–81). Antihypertensive use was common (n = 19/28, 68%). Product testing revealed no evidence of tampering, adulteration, endotoxin, or purity/potency issues. National adverse event trends were stable across 2016–2019 and 2020–2024.

Conclusions

SAEs, including deaths, can occur after ceftriaxone receipt. Product testing and trend analyses did not identify evidence of a new safety issue. This investigation highlights the need for ongoing vigilance for ceftriaxone SAEs and reporting to Food and Drug Administration MedWatch.

Schlagwörter

Stichwörter der Autor:innen

adverse eventsanaphylaxisceftriaxone

Autor:innen und Institutionen

  • Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Career Epidemiology Field Officer, Office of Readiness and Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Alabama Department of Public Health, Montgomery, AL, USA.
  • Arizona Department of Health Services, Phoenix, AZ, USA.
  • Arkansas Department of Health, Little Rock, AR, USA.
  • California Department of Public Health, Richmond, CA, USA.

ORCID-Profile: Rebecca Pierce, Radhika Agarwal, Maribeth C Lovegrove, Nimalie D Stone, Kelly M Hatfield, Jennifer Lind Lyles, Melissa Morrison, Scott Harris, Michael J Curran, Jenna Sinkevitch, Rachna Kapoor

Förderung

  • Centers for Disease Control and Prevention

Zitieren

APA

Pierce, R., Agarwal, R., Kayira, D., Lovegrove, M. C., Stone, N. D., Hatfield, K. M., Lyles, J. L., Morrison, M., Stubblefield, W., Davidson, S. L., Landers, K., Harris, S., Bhattarai, R., Dulski, T., Stoltey, J., Biehle, L., Hoffner, J., Charles, A., Wagner, J., …, & Adverse Event Investigation Group (2026). A Multistate Investigation of Serious Adverse Events, Including Deaths, Following Ceftriaxone Injections, September 2024–August 2025. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag521

Vancouver

Pierce R, Agarwal R, Kayira D, Lovegrove MC, Stone ND, Hatfield KM, et al. A Multistate Investigation of Serious Adverse Events, Including Deaths, Following Ceftriaxone Injections, September 2024–August 2025. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag521

BibTeX
@article{Pierce2026,
  author = {Pierce, Rebecca and Agarwal, Radhika and Kayira, Dumbani and Lovegrove, Maribeth C and Stone, Nimalie D and Hatfield, Kelly M and Lyles, Jennifer Lind and Morrison, Melissa and Stubblefield, Wes and Davidson, Sherri L and Landers, Karen and Harris, Scott and Bhattarai, Rachana and Dulski, Theresa and Stoltey, Juliet and Biehle, Lauren and Hoffner, Josh and Charles, Argentina and Wagner, JoAnna and Beeman, Haley and Curran, Michael J and Lee, Grace and Moore, Riley and Walters, Jacy and Patel, Gargi and Tran, Dat and Sinkevitch, Jenna and Tori, Marco and Wilson, Christopher and Godwin, Simone and Hussaini, Shehzana and Lafferty, Allison G and Bernard, Shaina and Ruelle, Shannon and Dasenbrock, Catherine O and Sheridan, Meredith and Wackes, Frank and Kapoor, Rachna and Gopalaswamy, Ramesh and Perkins, Kiran M and Adverse Event Investigation Group, Adverse Event Investigation Group},
  title = {A Multistate Investigation of Serious Adverse Events, Including Deaths, Following Ceftriaxone Injections, September 2024–August 2025},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciag521}
}
Kostenlos starten →